FOXA1 is a key pioneer factor in androgen-receptor activity but has been an elusive drug target. A new study shows that inhibition of the associated cofactor LSD1 modifies the methylation state of FOXA1, thus resulting in chromatin dissociation and tumor inhibition, even in models of treatment-resistant prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Lupien, M. et al. Cell 132, 958–970 (2008).
Augello, M. A., Hickey, T. E. & Knudsen, K. E. EMBO J. 30, 3885–3894 (2011).
Gao, S. et al. Nat. Genet. https://doi.org/10.1038/s41588-020-0681-7 (2020).
Cirillo, L. A. et al. EMBO J. 17, 244–254 (1998).
Zaret, K. S. & Carroll, J. S. Genes Dev. 25, 2227–2241 (2011).
Parolia, A. et al. Nature 571, 413–418 (2019).
Adams, E. J. et al. Nature 571, 408–412 (2019).
Cai, C. et al. Cell Rep. 9, 1618–1627 (2014).
Jozwik, K. M., Chernukhin, I., Serandour, A. A., Nagarajan, S. & Carroll, J. S. Cell Rep. 17, 2715–2723 (2016).
Kim, J. et al. Oncogene 36, 4072–4080 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Omarjee, S., Carroll, J.S. Targeting LSD1 and FOXA1 in prostate cancer. Nat Genet 52, 1002–1003 (2020). https://doi.org/10.1038/s41588-020-0702-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-020-0702-6
- Springer Nature America, Inc.
This article is cited by
-
FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer
Cell Death Discovery (2024)